Journal of Clinical Virology
Volume 29, Issue 3 , Pages 160-166, March 2004

Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C

  • Paolo Fabris

      Affiliations

    • Department of Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-0444-993-624; fax: +39-0444-993-616.
  • ,
  • Dave Brown

      Affiliations

    • Centre for Hepatology, Royal Free and University College Medical School, Rowland Hill Street, London, UK
  • ,
  • Giulia Tositti

      Affiliations

    • Department of Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
  • ,
  • Loredana Bozzola

      Affiliations

    • Department of Pathology, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
  • ,
  • Maria Teresa Giordani

      Affiliations

    • Department of Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
  • ,
  • Pierantonio Bevilacqua

      Affiliations

    • Department of Pathology, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
  • ,
  • Fausto de Lalla

      Affiliations

    • Department of Infectious Diseases and Tropical Medicine, S. Bortolo Hospital, Viale Rodolfi, Vicenza 36100, Italy
  • ,
  • George J.M. Webster

      Affiliations

    • Centre for Hepatology, Royal Free and University College Medical School, Rowland Hill Street, London, UK
  • ,
  • Geoffrey Dusheiko

      Affiliations

    • Centre for Hepatology, Royal Free and University College Medical School, Rowland Hill Street, London, UK

Received 30 December 2002; received in revised form 3 March 2003; accepted 15 April 2003.

Abstract 

Background: the frequency and the impact of occult HBV infection in patients with chronic hepatitis C infection is still a matter of some controversy. Objectives: our aim was to evaluate the prevalence of occult HBV infection and assess its impact on liver biochemistry, HCV viral titre, liver histology and on outcome of therapy in patients with chronic hepatitis C. Study design: paired liver biopsies and serum samples were collected from 51 patients (84% IVDUS) with HBsAg negative chronic hepatitis C, and tested for HBV-DNA with nested PCR. Liver biopsies were further studied histologically, with morphometric analyses and immunostaining techniques. Twenty-five were treated with alpha Interferon and ribavirin and followed for at least 18 months. Results: HBV DNA was detected in 29.4% of liver tissue specimens and in only one (1.9%) serum sample. Three liver specimens were positive for surface gene, nine for core gene, three for both and none for the X gene. No significant difference in mean transaminase values, HCV viral titre, HCV genotype, or grading and staging and morphometric analysis was observed in patients with or without HBV DNA. Moreover, all 51 liver specimens were negative for both HBsAg and HBcAg. Sustained response to combination therapy was achieved in 40% of patients with and in 53% of patients without HBV DNA in the liver specimens (P=NS). Conclusions: HBV DNA is frequently found in the liver of patients with chronic hepatitis C. However, the lack of any significant impact on HCV viral titre, liver enzymes, histological parameters and response to therapy, suggests that in most cases HBV DNA detected in the liver by PCR may be either an integrated or low level replicative form.

Keywords: Occult HBV infection, Hepatitis C virus, Hepatitis B virus, Hepatitis B virus-DNA, Liver histology, Interferon, Ribavarin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1386-6532(03)00117-3

doi:10.1016/S1386-6532(03)00117-3

Journal of Clinical Virology
Volume 29, Issue 3 , Pages 160-166, March 2004